190 results about "Basophils+Mast cells" patented technology

The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific VH, VL, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and / or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and / or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.

The invention discloses a novel application of bifidobacterium longum subsp. Infantis CCFM1269 in relieving atopic dermatitis, and belongs to the technical field of microorganisms. The bifidobacterium longum subsp. Infantis CCFM1269 provided by the invention can relieve atopic dermatitis, and is specifically reflected in that (1) ear swelling and back skin thickening of mice are relieved, dermatological symptoms are relieved, and mast cell infiltration is reduced; (2) reducing the total IgE level of serum; (3) the Treg level of mesenteric lymph nodes and the ILA content of serum are improved; (4) IL-4 and TSLP levels in skin tissues are reduced, IL-10 is improved, and Th1 / Th2 immune balance is recovered; (5) improving AHR and CYP1A1 in the skin tissue; and (4) high yield of ILA.

The invention relates to application of bifidobacterium breve BBr60 in preparation of a probiotic preparation for improving atopic dermatitis. The bifidobacterium breve BBr60 is a bifidobacterium breve BBr60 strain of which the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.12915, and the bifidobacterium breve BBr60 strain of which the preservation number is CGMCC No.12915. The invention develops a new application of the bifidobacterium breve BBr60, provides a research basis for wide application of the bifidobacterium breve BBr60, also develops a brand new strategy for improving atopic dermatitis, discovers that the bifidobacterium breve BBr60 has a very remarkable effect on improving atopic dermatitis, and has a very good application prospect. Specifically, the skin lesion phenomenon and the mast cell inflammation infiltration phenomenon in the skin of an atopic dermatitis model mouse are remarkably improved; the IgE level in serum of an atopic dermatitis model mouse is remarkably reduced and improved, the levels of IFN-gamma and IL-10 are improved, and Th1 / Th2 immune balance is recovered; the intestinal flora uniformity of atopic dermatitis model mice is recovered, and the relative abundance and F / B ratio of bifidobacterium and lactobacillus in the intestinal flora of the mice are remarkably improved.

Undesirable mast cell activity is associated with various diseases or conditions, such as allergy, inflammatory diseases, autoimmune diseases, and cancer. New and improved therapeutic agents that can target c-Kit and / or siglec-6 (e.g., for mast cell related diseases or disorders) still have been desired. Disclosed herein are molecules, such as antibodies and antibody fragments, capable of binding to c-Kit and / or siglec-6. Disclosed herein are molecules, such as antibodies and antibody fragments, capable of binding to c-Kit and / or siglec-6.

The invention belongs to the technical field of biological medicines, and particularly relates to application of quercetin combined with curcumin in preparation of an anti-allergic reaction medicine. Through a large number of researches, the inventor finds that combined administration of quercetin and curcumin with a specific concentration can effectively inhibit mast cell degranulation, and the inhibition rate of mast cell degranulation reaches 90% or more, so that I-type anaphylaxis mediated by immune globulin E is inhibited, especially systemic anaphylaxis, and the curative effect is good. The compound can be used for preparing anti-anaphylaxis drugs. The drug combination scheme provided by the invention has important significance and wide application prospect in drugs for treating or preventing anaphylactic reactions.

The invention belongs to the field of small molecule compound medicines, and relates to application of an APE1 inhibitor in preparation of a medicine for treating asthma. The invention provides a novel treatment strategy of asthma, discovers a new target APE1 for treating asthma, realizes an effective treatment effect on asthma by using an APE1 inhibitor C10 compound, can remarkably inhibit the inflammatory cell activity such as mast cells, eosinophilic granulocytes and lymphocytes of asthma, and can remarkably inhibit the inflammatory cell activity of mice lung pathology observation. The C10 compound disclosed by the invention has obvious relieving and relieving effects on lung pathological changes of asthma mice, so that the C10 compound can be clinically used for preventing or treating asthma, and has the industrial advantages of small molecular weight and simple synthesis process.

The present disclosure provides anti-Siglec-6 antibodies and their use in treating and preventing mast cell-mediated disorders, as well as compositions and kits comprising the anti- Siglec-6 antibodies.

The invention discloses a novel application of bifidobacterium breve CCFM1078 in relieving atopic dermatitis, and belongs to the technical field of microorganisms. The bifidobacterium breve CCFM1078 provided by the invention can relieve atopic dermatitis, and is specifically reflected in that (1) ear swelling and back skin thickening of mice are relieved, dermatological symptoms are relieved, and mastocyte infiltration is reduced; (2) the relative expression quantity of mRNA (messenger Ribonucleic Acid) of mouse skin barrier function related genes is increased; (3) reducing the total IgE level of mouse serum; (4) reducing the levels of IL-4, IL-13 and TSLP in mouse skin tissues, improving the levels of IL-10 and IFN-gamma, recovering Th1 / Th2 immune balance, and maintaining immune homeostasis; (5) activating the expression of AHR and CYP1A1 in the skin tissue of the mouse; (6) improving IgA and sIgA secretion of mouse colon tissue; and (7) compared with a representative high-yield ILA strain, the ILA yield is higher.

The invention provides a specific binding polypeptide of a targeted cell membrane receptor Fc epsilon RI alpha and application of the specific binding polypeptide. The amino acid sequence of the polypeptide is shown in any one of (I) SEQ ID NO: 1-6; (II) an amino acid sequence with at least 90% identity as shown in any one of SEQ ID NO: 1-6, and is specifically combined with a cell membrane receptor Fc epsilon RI alpha. Experimental results show that the Fc [epsilon] RI [alpha] specific binding polypeptide can inhibit IgE-mediated mast cell dependent anaphylaxis to a certain extent, which prompts that the Fc [epsilon] RI [alpha] specific binding polypeptide has a certain inhibition effect on IgE-mediated I-type anaphylaxis, and lays a foundation for further research and development of novel biological targeting drugs for treating allergic diseases.

The invention discloses a PD-1 treatment responsiveness-oriented tumor microenvironment targeting cell enrichment method for a gastric cancer patient. On the basis that a ligand-receptor shows more significant correlation to the change of the expression level of VEGFA-FLT1 in the tumor tissue of the gastric cancer and the responsiveness of immunotherapy, a sufficient number of Mast cells and Endothelial cells are separated and obtained from the tumor tissue of a patient with the gastric cancer, and the expression level change of VEGFA-FLT1 in the tumor tissue of the gastric cancer and the responsiveness of the Endothelial cells in the tumor tissue of the patient with the gastric cancer show more significant correlation. The method can be used for making up for the deficiency of a single marker in improving the accuracy of immunotherapy responsiveness evaluation, so that the realization of future precise individualized immunotherapy of gastric cancer is better promoted.

The application discloses application of volatile oil of Citrus aurantium in preparation of a medicine for preventing and treating allergic rhinitis. The application proposes that the volatile oil of Citrus aurantium can significantly reduce the levels of mast cell factors IL-1beta and TNF-alpha, and can also significantly reduce the levels of inflammatory factors IL-13 and IL-4 in mice, reduce inflammatory cell infiltration, and reduce eosinophilic granulocyte increase and gland hyperplasia. The application proposes that the volatile oil of Citrus aurantium has great potential as a medicinal and edible raw material for treating allergic rhinitis. The application also proposes that the volatile oil of Citrus aurantium can significantly improve symptoms such as sneezing, runny nose, and nasal itching of mice caused by allergic rhinitis, and the symptoms seriously affect the life of patients.

The invention provides methods and compositions that are useful for treating allergic diseases, bacterial infections, fungal infections, viral infections, mastocytosis, mast cell-mediated inflammation and parasite infections (e.g., helminth infections).

Provided herein are antibodies and antibody fragments relating to SIGLEC-8 and CD117. Provided herein are methods and compositions relating to SIGLEC-8 and / or CD117 libraries having nucleic acids encoding for a scaffold comprising a SIGLEC-8 and / or CD117 domain. SIGLEC-8 and / or CD117 libraries described herein encode for immunoglobulins such as antibodies.

To provide methods for managing, treating, or preventing an eosinophil or mast cell related disorder and / or one or more symptoms thereof, for example a mast cell related disorder of the nervous system, e.g., central nervous system, for example neuromyelitis optica (NMO), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and neurofibromatosis (NF).SOLUTION: The present invention provides a method including administering to a subject in need thereof a therapeutically effective amount of an antibody which specifically binds to a KIT receptor tyrosine kinase.SELECTED DRAWING: None

The invention discloses application of a mast cell polarization typing detection kit, and belongs to the field of biological medicine. The kit comprises a mast cell characteristic enzyme TPSB2 detection reagent, and one or more of a mast cell MC1 type polarization detection reagent and a mast cell MC2 type polarization detection reagent, the MC1 type polarization is CCL27, and the expression of TNF-alpha is up-regulated; and the MC2 type polarization comprises expression up-regulation of CCL3, IL-16 and VEGFA (vascular endothelial growth factor A). Mstoma cells have dual effects in a tumor microenvironment, can promote tumor progression, and also can enhance anti-tumor immune response. The mastocyte polarization typing is identified through the expression level of the biomarker, so that the mastocyte polarization typing can be rapidly and accurately evaluated, identification indexes and tools are provided for further discussing the functions of mastocytes in different polarization states, cancer diagnosis can be assisted, the onset risk of cancer can be reduced, and the method is suitable for popularization and application. And an immunotherapy target is provided for clinical treatment of cancers.

This invention provides a method for constructing a fluorescently traced mouse model and its application in the sorting of Mcpt4-positive and negative mast cells. First, the Cre gene is knocked into the Mcpt4 gene sequence of C57BL / 6 mice using CRISPR / Cas9 technology. Then, through animal hybridization and Cre-loxP recombination technology, a fluorescently traced mouse model of Mcpt4-positive mast cells is obtained. The fluorescently traced mouse model possesses a dual-fluorescent reporter gene system consisting of the red fluorescent protein tdTomato and the green fluorescent protein ZsGreen. Mcpt4-positive mast cells exhibit red fluorescence, while other Mcpt4-negative cells exhibit green fluorescence. Using this fluorescently traced mouse model, Mcpt4-positive and negative mast cells can be rapidly, accurately, and effectively sorted, providing a reliable technical basis for exploring the roles and mechanisms of Mcpt4-positive and negative mast cells in immune responses.

The application provides an anti-urticaria traditional Chinese medicine composition, a medicine preparation and a preparation method and application, and belongs to the field of traditional Chinese medicine compositions. The traditional Chinese medicine composition is composed of the following raw materials: 12-18 parts of Fructus Mume, 8-12 parts of Glycyrrhiza, 12-18 parts of Imperata Cylindra, 8-12 parts of Smilax Glabra, 8-12 parts of Coix Lachryma-jobi, 8-12 parts of Radix Angelicae Dahuricae, 5-7 parts of Mentha, 5-7 parts of Astragalus, 8-12 parts of Pericarpium Citri Reticulatae, and 8-12 parts of Momordica Grosvenorii. The composition follows the compatibility principle of monarch, minister, assistant and messenger, has mild medicinal properties, can significantly improve the histopathological damage of skin tissues, reduce the infiltration of mast cells, reduce the serum IgE level, correct the Th1 / Th2 immune deviation by up-regulating the Th1-type cytokine IFN-gamma and down-regulating the Th2-type cytokines IL-4, IL-5 and IL-13, and reconstruct the local immune homeostasis of skin, and has significant advantages in relieving the symptoms of urticaria and reducing the recurrence.

The invention relates to a method for depleting mast cells. The invention also relates to a method of treating mast cell disease in a subject in need thereof. The method involves administering an anti-mast cell antibody wherein the antibody is administered by a slow absorption delivery pathway, in particular wherein the antibody is administered subcutaneously. Administration of anti-mast cell antibodies via a slow absorption delivery pathway (e.g., subcutaneous or intradermal) can avoid allergic reactions occurring when anti-mast cell antibodies are administered via other pathways (e.g., intravenous).

Disclosed are small molecule c-kit inhibitors useful in reducing or eliminating mast cell mediated inflammation. Pharmaceutical formulations containing the c-kit inhibitors are also disclosed. Additionally, methods of treating or preventing a condition, disorder, or disease using the c-kit inhibitors or pharmaceutical formulations thereof are disclosed. The condition, disorder, or disease may be an inflammatory condition, including flares of the inflammatory condition. Exemplary inflammatory conditions relevant to this disclosure include, but are not limited to, mastocytosis, mast cell activation syndrome, hereditary alpha tryptasemia, urticaria, Lyme disease, mast cell leukemia, chronic obstructive pulmonary disease, long COVID, asthma, inflammatory bowel disease, arthritis, allergy, and gout.

A collagen-boosting supplement that contains at least 4, optionally at least 10, collagen building block amino acids and is substantially free of histidine. The building block amino acids may be selected from: Glycine, L-Proline, L-Hydroxyproline, L-Glutamic Acid, L-Alanine, L-Arginine, L-Aspartic Acid, L-Serine, L-Leucine, L-Lysine, L-Hydroxylysine, L-Valine, L-Phenylalanine, L-Threonine, L-Isoleucine, L-Methionine, and L-Tyrosine. The supplement may further comprise: vitamin C; one or more mast cell stabilisers which may be selected from: quercetin, molybdenum, bromelain, DAO (diamine oxidase), Urtica Dioica (stinging nettle), Nigella Sativa (black cumin), Zingiber (ginger), Scutellaria baicalensis (Chinese skullcap), Sambucus (Elderberry), Aloe Vera, Syzygium aromaticum (clove), and matcha; one or more collagen-strengthening herbs which may be selected from: Bilberry, Centella, and Astragulus; one or more Glucosaminoglycans (GAGs) which may be selected from: Hyaluronic acid, glucosamine, and chondroitin; one or more antioxidants which may be selected from: astaxanthin and resveratrol; and / or one or more cofactors which may be selected from: zinc, biotin, silicon, manganese, magnesium, Vitamin D, Vitamin A, Vitamin E, and iron. The supplement may be a foodstuff, medicament, nutraceutical, or cosmetic. The supplement may be used to treat hypermobile Ehlers-Danlos syndrome (hEDS) while reducing the likelihood of mast cell degranulation through histamine activation.

The invention discloses a substance with anti-allergic activity and application thereof, the substance with anti-allergic activity is a bitter receptor stimulant, and the bitter receptor stimulant is selected from at least one of denatonium benzoate, difenidol and quinine. The compound can reduce the expression level of IgE in serum, inhibit mast cell degranulation and regulate and control expression of cytokines at the downstream of Th1, Th2 and Dc cells, so that allergy is prevented and allergic symptoms are relieved, and the compound can be used for preparing medicines, health foods, functional foods and dietary supplements for preventing and relieving food allergy.

The disclosure relates to pharmaceutical formulations and method of using chymase inhibitors for the prevention and treatment of mast cell-related disease states in which chymase is involved. More particularly the present disclosure is in the field of treating or preventing or reducing the symptoms of mast cell-related diseases, including atopic dermatitis (AD), chronic urticaria (CU), Eosinophilic Gastrointestinal Disorders (EGIDs), and prurigo nodularis (PN), using a chymase inhibitor, including a chymase inhibitor that prevents cleavage of stem cell factor (SCF) and its interaction with receptor tyrosine kinase (c-kit), thereby reducing mast cell activation and proliferation.

The present disclosure relates to the use of IgE for identifying individuals with genetic defects that lead to the expression of protein truncations, extended proteins, to a loss of protein expression or to the expression of mutated proteins. The method is based on a skin prick test, wherein IgE that is specific for the protein of interest is administered onto the skin. If the protein or protein variant that is specifically identified by IgE is present in the skin, the IgE, which was allowed to enter the skin by the skin prick, binds the target protein and then the protein-bound IgE triggers mast cells and / or basophiles in the skin to release granules, resulting in the development of a transient allergic reaction.

The invention discloses a near-infrared ratio type fluorescent probe for rapidly and reversibly detecting histamine (HA), a preparation method of the fluorescent probe and application of the fluorescent probe in dynamic cell imaging, and belongs to the technical field of fluorescence imaging and biosensing. The preparation method comprises the following specific steps: synthesizing aza-BODIPY molecules (1a-1d, 2a-2d) with different halogenations, and meanwhile, connecting the aza-BODIPY molecules with hydroxyl groups at 3 and 5 sites with a hydrophilic PEG (Polyethylene Glycol) fragment and halogen to obtain an HA probe HAPCyto with good water solubility; in addition, the hydroxyl aza-BODIPY molecules are continuously subjected to substitution, halogenation and hydrolysis reaction to obtain carboxyl-containing aza-BODIPY molecules, then the aza-BODIPY molecules are subjected to amidation reaction by utilizing the site, and different organic fragments are respectively connected to obtain a cell membrane targeted HA probe HAPPM, a golgi apparatus targeted HA probe HAPGA and a HaloTag HA fluorescent probe HAPHaloTag. When HA exists in a solution, the developed probe can realize rapid reversible detection of the near-infrared ratio of histamine, also shows good reversible property in mast cells, and can realize dynamic monitoring of histamine in cells.

The invention relates to the field of medicines, in particular to application of LKB1 / AMPK pathway-based fucoidan in preparation of anti-type I anaphylaxis medicines. The LKB1 / AMPK pathway is activated by the alginate, so that mast cell degranulation is effectively inhibited, mast cell mediated cell anaphylaxis is further effectively inhibited, and the alginate can be used for preparing anti-anaphylaxis related drugs.

The disclosure demonstrates the role of mast cell stabilizers in treating rosacea. The disclosure also shows the role of mast cells, cathelicidin, serine protease and / or vitamin D3 in rosacea pathology and the use of antagonists and inhibitors thereof to treat rosacea.

The present invention relates to a composition for preventing, alleviating or treating skin wounds, comprising exosomes of mast cells. The composition according to the present invention enhances the growth and activity of fibroblasts, and thus has the effects of significantly reducing the size of wounds and shortening an initial wound treatment period.

The invention discloses an application of a nitrobenzene-containing urea compound in preparation of an anti-allergic reaction drug, and the nitrobenzene-containing urea compound can be applied in preparation of a drug for antagonizing mouse sole swelling and plasma exosmosis caused by C48 / 80. The invention also discloses application of the compound in preparation of drugs for antagonizing mouse sole skin vasodilation and mast cell degranulation caused by C48 / 80. The nitrobenzene-containing urea compound can effectively relieve mouse sole swelling and plasma exosmosis, mouse sole skin vasodilation and mast cell degranulation caused by C48 / 80, reduce serum histamine release and relieve body temperature decline, so that the occurrence of anaphylactoid reaction is inhibited, and the nitrobenzene-containing urea compound can be used for preventing and treating hyperplasia. Therefore, when the nitrobenzene-containing urea compound is used as an anti-drug anaphylaxis preparation, more possible treatment schemes are provided for clinical drug anaphylaxis treatment.

The invention provides pediococcus acidilactici with functions of improving emotion and intestinal health and application of the pediococcus acidilactici. The pediococcus acidilactici A25-4 is preserved in Guangdong Microbial Culture Collection Center on May 23, 2025, and the preservation number of the pediococcus acidilactici A25-4 is GDMCC NO: 66384. The pediococcus acidilactici A25-4 has better cholate resistance and artificial gastrointestinal fluid resistance and can produce indole lactic acid ILA at high yield, and the optimal carbon source is fructo-oligosaccharide and galactooligosaccharide. The pediococcus acidilactici A25-4 in-vivo intervention can significantly improve the symptoms of an irritable bowel syndrome model mouse, specifically, the anxiety mood of a tested object is significantly improved; the viscera hypersensitivity of a tested object is obviously relieved; excessive activation of mast cells of a tested object is obviously inhibited; the ILA level in a tested object is obviously improved.

The present application relates to the technical field of skin care products, and discloses a composition with the effect of soothing sensitive skin, which is composed of the following components in mass percentage: plant extract 10-12%, skin repair factor 2-3%, jasmine hydrolat 10%, humectant 6-7%, and the balance being water. The composition with the effect of soothing sensitive skin has significant soothing effect, which is close to the soothing effect of common hormone ointments on the market. The composition can significantly reduce inflammatory factors, has good anti-inflammatory effect, simultaneously repairs damaged skin, enhances the moisturizing function, and enhances the skin barrier through the moisturizing and repairing effect. The composition has the effect of resisting anaphylaxis by reducing the content of trypsin and inhibiting the allergic reaction of mast cells. Human patch test and fish embryo development toxicity test prove that the composition with the effect of soothing sensitive skin has no skin adverse reactions and no development toxicity, is mild, safe and non-irritating, and is suitable for preparing skin care products for adults and infants.